Business news

    US markets climb; Microsoft rallied on Q1 results; Pfizer rallied on US FDA authorisation recommendation.

    Article Image
    Highlights
    • The Nasdaq rose 0.1% to close Tuesday?s session at 15,236.
    • Microsoft rallied after-hours following the release of strong Q1 results.
    • Pfizer rallied after committee advised the US FDA to approve its vaccine for 5-11 YO.

    The US markets inched higher on Tuesday as investors responded to strong corporate quarterly earnings results from big banks, consumer companies, manufacturers and big tech companies.

    The Dow Jones rose 0.04% to finish the trading day up 16 points to close at 35,757 points.

    The tech heavy NASDAQ rose 0.1% to finish the trading day up 9 points to close at 15,236 points with Amazon and Google gaining 1.68% and 0.65% respectively.

    One bitcoin is worth US$60,455 going into the Asian trading day.

    The Australian dollar is firm against the major currencies and is buying 75.03 US cents.

    Microsoft shares rallied in after-hours trade following the release of the tech giants? first quarter results that easily exceeded analysts expectations and estimates. For the period, Microsoft reported revenue growth of 22% YoY to US$45.32bn, well above estimates of US$43.97bn, EPS came in at US$2.27/share and net income growth of 48% to US$20.5b, with Microsoft attributing the results to ongoing strength in its cloud business.

    Pfizer shares also rallied in after-hours trade on the back of the committee of experts advising the US FDA recommending the regulatory body should approve Pfizer & BioNTech?s COVID-19 vaccine for administration in children aged 5-11 years. The panel concluded that the benefits of the vaccine outweigh the potential risks.

    And Elon Musk?s net worth surged by US$26bn in just one day as Tesla shares surged 12% to push Tesla?s market value over US$1tn.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa